<unk> , and antibiotics<unk>  cannot be spread from person to person, except in the rare case of skin exudates from cutaneous<unk> . However, a person's clothing and body may be contaminated with<unk>  spores. Effective decontamination of people can be accomplished by a thorough wash-down with antimicrobial soap and water. Wastewater is treated with bleach or another antimicrobial agent. Effective decontamination of articles can be accomplished by boiling them in water for 30 minutes or longer. Chlorine bleach is ineffective in destroying spores and vegetative cells on surfaces, though formaldehyde is effective. Burning clothing is very effective in destroying spores. After decontamination, there is no need to immunize, treat, or isolate contacts of persons ill with<unk>  unless they were also exposed to the same source of infection. Antibiotics Early antibiotic treatment of<unk>  is essential; delay significantly lessens chances for survival. Treatment for<unk>  infection and other bacterial infections includes large doses of intravenous and oral antibiotics, such as fluoroquinolones (ciprofloxacin), doxycycline, erythromycin, vancomycin, or penicillin. FDA-approved agents include ciprofloxacin, doxycycline, and penicillin. In possible cases of pulmonary<unk> , early antibiotic prophylaxis treatment is crucial to prevent possible death. Many attempts have been made to develop new drugs against<unk> , but existing drugs are effective if treatment is started soon enough. Monoclonal antibodies In May 2009, Human Genome Sciences submitted a biologic license application (BLA, permission to market) for its new drug, raxibacumab (brand name<unk>  intended for emergency treatment of inhaled<unk> . On 14 December 2012, the US Food and Drug Administration approved raxibacumab injection to treat inhalational<unk> . Raxibacumab is a monoclonal antibody that neutralizes toxins produced by B.<unk> is. In March 2016, FDA approved a second<unk>  treatment using a monoclonal antibody which neutralizes the toxins produced by B.<unk> is. Obiltoxaximab is approved to treat inhalational<unk>  in conjunction with appropriate antibacterial drugs, and for prevention when alternative therapies are not available or appropriate.
Anthrax
Plague 
Spanish flu
Rubella
Metal fume fever
Great Plague of London
Trench fever
Scrub typhus